Optimizing patient selection for dose escalation techniques using the prostate-specific antigen level, biopsy gleason score, and clinical T-stage
- 1 December 1999
- journal article
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 45 (5) , 1227-1233
- https://doi.org/10.1016/s0360-3016(99)00303-x
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- RADICAL PERINEAL PROSTATECTOMY: ONCOLOGICAL OUTCOME DURING A 20-YEAR PERIODJournal of Urology, 1999
- A relationship of local prostate dose and subsequent metastasis with 3D CRT in prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 1998
- 3D conformal radiation therapy (3DCRT) for high grade prostate cancer: A multi-institutional reviewInternational Journal of Radiation Oncology*Biology*Physics, 1998
- Defining the appropriate dose for prostate cancer patients with PSA<10ng/mlInternational Journal of Radiation Oncology*Biology*Physics, 1998
- Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate CancerJAMA, 1998
- Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and GoserelinNew England Journal of Medicine, 1997
- Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level ≤ 10 ng/ml: Radiation therapy or surgery?International Journal of Radiation Oncology*Biology*Physics, 1997
- Analysis of prostate and seminal vesicle motion: Implications for treatment planningInternational Journal of Radiation Oncology*Biology*Physics, 1996
- Free, Complexed and Total Serum Prostate Specific Antigen: The Establishment of Appropriate Reference Ranges for their Concentrations and RatiosJournal of Urology, 1995
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958